Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, has closed on a registered direct offering of 1,146,552 of the company’s … Continue reading →

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. The company today announced its entry into a definitive agreement … Continue reading →

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., today announced that its CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New … Continue reading →